Catalyst Biosciences : Investor presentation 1.6 MB

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including, without limitation, the amount and timing of planned cash distributions under the contingent value rights agreement the ("CVR"); expectations regarding the proposed transactions with entities affiliated with GNI Group Ltd., including Beijing Continent Pharmaceuticals Co. Ltd. ("Beijing Continent"), the expected benefits and timing of the closing of the proposed transaction; the potential market opportunity for and expected development of Hydronidone (F351) in nonalcoholic steatohepatitis ("NASH") and liver fibrosis; the safety and tolerability profile of Hydronidone (F351); the association of clinical data with potential clinical benefit; and statements regarding the potential of, and expectations regarding, Beijing Continent's programs. In some cases, you can identify forward-looking statements by terms such as "anticipate," "design," "expect," "potential," "plan," or the negative of these terms, and similar expressions intended to identify forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risks that the proposed business combination with Beijing Continent will not be completed in a timely manner, if at all; the risk that the development of Hydronidone (F351) in NASH and liver fibrosis will not be successful or require more capital than anticipated; the risk that results from the Phase 2 trial of Hydronidone (F351) in hepatitis related fibrosis will not be replicated in subsequent trials, and other risks described in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission ("SEC") as well as the proxy statement and registration statement on Form S-3 to be filed with the SEC by Catalyst. We disclaim any obligation to update any forward-looking statements, except as required by law.

CBIO corporate strategy

Generate further value for stockholders

December 2022

• Acquired global rights (excluding China) to Hydronidone (F351), a drug designed to treat NASH and liver fibrosis
• Plan to acquire a controlling interest in Beijing Continent, a commercial biopharmaceutical company based in China, from the GNI Group Ltd. and related parties
• Announced $7.5 million special dividend and CVR

2023

• Completed $6 million asset sale of compounds designed to treat rare bleeding disorders to GC Biopharma, with net proceeds to be distributed to CVR holders
• Annual Meeting of Stockholders expected to be held mid-2023

CBIO 2023 corporate strategy

Transition Our Focus to Organ Fibrosis

• Expect to consummate Beijing Continent business combination in mid-2023
• Planning development of Hydronidone (F351) for NASH in the United States
• Beijing Continent expected to complete enrollment of Phase 3 trial in Hydronidone (F351) for hepatitis B virus ("HBV")-associated liver fibrosis in China
• Distribute remaining net cash from legacy assets to CVR holders